Two beta-lactam antibiotics, cefazolin and cefmenoxime, were administered for 7 days to mice with pneumonia caused by Klebsiella pneumoniae by using dosage regimens that would simulate multiple dosing in usual clinical treatments at dosing intervals of 8 or 12 h. Viable numbers of the bacteria in the lungs were measured at 12-or 24-h intervals. The mathematical model established in a previous single-dose study was applied in this study to explain the time courses of the changes in bacterial count over 7 days. However, because the error in viable count measurements was larger than that in the previous study, the time course of the changes in mean viable count was not regular and the viable count reduction rate changed during multiple dosing, and therefore it was difficult to explain the time course by repeated application of the mathematical model described previously. This study suggests that the changes in pharmacokinetic and pharmacodynamic parameters during multiple dosing need to be considered.
In a previous report (3), we applied a mathematical model to the bacterial killing curves observed during experimental treatments by using two beta-lactam antibiotics, cefazolin and cefmenoxime, and a fatal murine pneumonia model. The drugs were administered to the infected mice by using dosage regimens that resulted in serum antibiotic levels that simulated those in humans after single-drip infusions. The mathematical model explained the bacterial count at time t after dosing by using the pharmacokinetic and pharmacodynamic parameters.
Continuing along the same lines as the previous study, which was considered to be a simulation of single dosing in humans, we performed the present study as a simulation of multiple dosing in humans. By considering multiple dosing with interval time t, the model described above can be applied repeatedly by taking the bacterial count at time t after the previous dose as the initial count for the succeeding dose. We can thus predict the time at which complete clearance of bacteria will be achieved if the numerical values of the pharmacokinetic and pharmacodynamic parameters do not change throughout the dosing period.
For each drug we determined two intervals, one that would produce and one that would not produce complete clearance in several days, and tested for the feasibility of applying the mathematical model to multiple dosing. MATERIALS AND METHODS Animals. A total of 150 male DDY mice were infected with Klebsiella pneumoniae B-54 with an initial inoculum of 500 times the 50% lethal dose, that is, 5 x 104 CFU per mouse, and were then subjected to antibiotic therapy 24 h later. These mice were 3 weeks old and weighed about 12 g.
Bacteria. K. pneumoniae B-54 was isolated from a patient with very severe pneumonia in 1978. The 50% lethal dose of this strain was 9.7 x 10 CFU per mouse in this experimental pneumonia model. * Corresponding author.
Antibiotics. Cefazolin (Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan) and cefmenoxime (Takeda Chemical Industries Ltd., Osaka, Japan) were used. The MICs of cefazolin and cefmenoxime against K. pneumoniae B-54 were measured by the agar well method. The MIC of cefazolin was 1.56 ,ug/ml, and the MIC of cefmenoxime was 0.013 ,ug/ml. Antibiotic assay. Cefazolin and cefmenoxime in plasma samples were assayed by the agar well method with Escherichia coli NIHJ as the test organism. The sensitivity was about 0.1 ,ug/ml, and the coefficient of variation from replicate analyses between days was ±7.0%, as in the previous study (3) . Doses and dosage regimens. Table 1 shows the dosing regimen which was established in the previous study (3) a The multiple subcutaneous injection in mice was established in the previous study (3) to simulate the serum concentration time course in humans when the drugs were given by single-drip infusion over 1 h. Repetition of this regimen was considered to simulate multiple drip infusions in humans. By using the differences between AUCs for mice and those for humans, the total doses for mice were converted to the corresponding doses for humans; 17.0 and 20.3 mg/kg for cefazolin and cefmenoxime, respectively.
variation from replicate measurements within a day was about +5.0%, in log1o CFU.
The mathematical model and estimation of parameters. The mathematical model for single dosing was established in the previous study (3) as
where Cb and CbO are the bacterial counts at time t and t = 0 after the initial dose, respectively, Kb and K are the rate constants of bacterial growth and antimicrobial killing, respectively, D is the dose of the drug administered, n is the degree of antibiotic distribution into the tissue, E is the time lag between drug concentration time courses in serum and that in lung, and Ai and Pi are pharmacokinetic macro-and microconstants in a two-compartment model, respectively (i = 1, 2).
The parameters were estimated in the previous study as 
Given the above parameter values of Kb, K, n, Ai, and Bi (i = 1,2), the data of bacterial counts for each regimen were subjected to least-squares analysis by using equation 4 to give the estimates of M. If M = 1, the killing curve under multiple dosing is the complete repetition of the single wave obtained in the previous single-dose study, while M > 1 and M < 1 lead to faster and slower bacterial reductions, respectively. Choanges in observed bacterial counts. The initial mean log1o CFU was 6.97 in all the treatment groups, and good agreement was noted with the value of 6.94 obtained in the previous study (3) . Twice-daily treatment with cefazolin produced little bacterial count reduction, and treatment three times a day reduced the number of bacteria to a residual mean log1o CFU of 1.64 on day 7. In contrast, both twice and three times daily treatmnent with cefmenoxime gave rapid reduction, yielding residual mean log1o CFUs of 1 steep reduction on day 4, followed by bac the detection limit in the remaining days.
While bacterial counts, as a whole, were the case of twice-daily treatment with c course did not show a monotone decrea exhibited a transient increase.
Variance between observations. SDs o from each three mice was maximally 2.' fazolin at 12-h intervals at the 72-h time pi servational variances at all time points we treatment group, which resulted in pooled CFU (SDs are given in parentheses), as fi lin at 12-h intervals, 3.07 (1.75); for cefazo 2.17 (1.47); for cefmenoxime at 12-h inte and for cefmenoxime at 8-h intervals, 2.4
Each of the cefmenoxime groups exhibi the later period of treatment when the bac stabilized at lower levels, giving a log1o mately 0.8.
In the previous study (3), on the othe each measurement time point was ma)
to CFU, while the pooled mean SD for each treatment group was maximally 0.84 log1o CFU. The variability in observations in the present study was large compared with that in the previous study.
Estimates of M and simulated killing curves. The dotted waves in Fig. 1 through 4 are the simulated time courses of log1o CFU by using M = 1 predicted from the single-dose study, and the solid waves are those obtained by using the estimated M values.
For 12-h intervals. The 12-h interval simulation represented by the dotted curves in Fig. 1 through 4 The mathematical model for multiple dosing described 2-44 (1i56)a here is appropriate when the viable count log1o CFU de-7). (1.6) creases linearly with time. However, since no regular monoialler SDs in tone reduction was observed, the simple repetition of the counts were curve generated from the previous single-dose study ( The causes of nonmonotone changes in the mean observed values include, first, the large errors in log1o CFU'; second, the small number of animals used, which led to somewhat unreliable mean values per measurement time point; and third, possible irregular changes in pharmacokinetic and pharmacodynamic parameters during multiple dosing. Such changes in in vivo antimicrobial activity during multiple dosing could be affected by the changes in the pharmacokinetic parameters AUC, maximum concentration of drug in serum, and duration of time levels exceed the MIC (t-MIC) and in the pharmacodynamic parameters postantibiotic effect, postantibiotic leukocyte enhancement, drug distribution into the tissue, and susceptibilities of organisms.
Concerning pharmacokinetic parameters, Drusano (2), Leggett et al. (4) , and Vogelman et al. (10) showed that t-MIC is the most important parameter in the case of A r-T hr beta-lactams and gram-negative bacilli. As pneumoniae, while neither of the treatments did so when they were conducted at 12-h intervals. This insufficiency may have caused the gaps in viable counts seen between treatments at 8-and 12-h intervals. With respect to pharmacodynamic factors, Mattie and van der Voet (7) reported that the killing and growth rates were covariable and could change during the dosing period. Vogelman et al. (10) showed the phenomena termed postantibiotic effect and postantibiotic leukocyte enhancement. Tuomanen et al. (9) reported phenotypic tolerance in the stationary phase of growth and stated that the antimicrobial effect generally appears after the onset of growth of microorganisms.
However, the changes in pharmacokinetic and pharmacodynamic factors during multiple dosing have not yet been studied.
During multiple dosing, host-dependent factors become important, in addition to the changes in pharmacokinetic and pharmacodynamic parameters. The K. pneumoniae-infected mice used in this study were nonneutropenic, and their susceptibilities to K. pneumoniae could affect the in vivo antimicrobial effects. For example Coonrod (1), MacDonald et al. (5), and Roosendaal et al. (8) described phagocytosis by neutrophiles as a host-dependent factor. Matsumoto et al. (6) have considered that histopathological findings of the infectious focus change from the initial stage of infection to the maturing and healing stages and histological changes become more complicated with the addition of chemotherapy.
Although no histopathological examinations were conducted in the present study, it is reasonably assumed that, if interindividual differences were increasingly enhanced in the course of multiple dosing with respect to the size of the infected lesion and the histopathological picture of the mice, errors in log1o CFU may have been magnified compared with the case of single dosing.
These host-related factors would naturally exert some influence on the pharmacokinetic and pharmacodynamic factors, leading to changes in the antibacterial effect and the nonmonotone time course of bacterial count.
In the mathematical model reported previously (3), parameter E is related to the duration of the antimicrobial action, with larger E values being associated with prolonged effects, while the parameters K and n are related to the strength of the effect, with larger values of K and n indicating stronger activity. To follow up changes in the individual parameters Kb, K, E, and n during multiple dosing, more frequent bacterial counting concentrated in a shorter period will have to be repeated intermittently, unlike in the present experimental design for multiple dosing, which was based on measurement at equal intervals over a long duration. Furthermore, if the tissue drug levels could be determined along with the bacterial count, the substantial effect of the nonmonotone change, if any, would be explained.
